阅读说明：本技术 一种用于创口愈合的复合细胞制剂 (Composite cell preparation for wound healing ) 是由 魏伟 嵐山芮 袁嘉恩 许超 于 2020-12-30 设计创作，主要内容包括：本发明提供一种用于创口愈合的细胞制剂,包括以下重量份的组分：聚丙烯酰胺10～50份、化壳聚糖季铵盐2～25份、槲皮素1～25份、富含血小板血浆1～20份。本发明提供的用于创口愈合的细胞制剂,含有脐带血来源的富含血小板血浆,具有丰富的纤维蛋白,比成人外周血更有效支持伤口愈合。通过富含血小板血浆与槲皮素的协同增效,加快伤口愈合,提高创面修复率,缩短创面修复时间,在涂抹本发明细胞制剂的第8天,创面修复率能打到60％以上,最快12天能完全愈合。(The invention provides a cell preparation for wound healing, which comprises the following components in parts by weight: 10-50 parts of polyacrylamide, 2-25 parts of chitosan quaternary ammonium salt, 1-25 parts of quercetin and 1-20 parts of platelet-rich plasma. The cell preparation for wound healing provided by the invention contains platelet-rich plasma derived from umbilical cord blood, has abundant fibrin, and more effectively supports wound healing than adult peripheral blood. By the synergistic effect of the platelet-rich plasma and the quercetin, the wound healing is accelerated, the wound repair rate is improved, the wound repair time is shortened, the wound repair rate can reach more than 60% on the 8 th day after the cell preparation is smeared, and the wound can be completely healed in 12 days at the fastest speed.)

1. A cell preparation for wound healing is characterized by comprising the following components in parts by weight: 10-50 parts of polyacrylamide, 2-25 parts of chitosan quaternary ammonium salt, 1-25 parts of quercetin and 1-20 parts of platelet-rich plasma.

2. The cellular preparation for wound healing according to claim 1, wherein the volume ratio of quercetin to platelet rich plasma is 1-9: 1-9.

3. The cell preparation for wound healing of claim 2, wherein the cell preparation for wound healing has a volume ratio of quercetin to platelet rich plasma of 1: 1.

4. The cell preparation for wound healing according to claim 1, which comprises the following components in parts by weight: 20-40 parts of polyacrylamide, 10-20 parts of chitosan quaternary ammonium salt, 5-10 parts of quercetin and 10-15 parts of platelet-rich plasma.

5. A cell preparation for wound healing according to claim 4, comprising the following components in parts by weight: 30 parts of polyacrylamide, 15 parts of chitosan quaternary ammonium salt, 10 parts of quercetin and 10 parts of platelet-rich plasma.

Technical Field

The invention belongs to the field of cell therapy, and particularly relates to a composite cell preparation for wound healing.

Background

For years, the most common clinical wound suturing method is to suture by materials or apparatuses such as suture lines, rivets and the like, the method ensures the tensile strength, but can increase the pain of patients, leave scars after wound healing and is troublesome to operate. With the rapid development of modern medicine, the clinical requirements for wound adhesion are higher and higher, so that the requirements for minimizing the pain of a patient and shortening the healing time are met, and the appearance can be perfectly recovered while the function is recovered.

For traumatic wounds, a common method is to apply a bandage or a lotion, and if the wound is deep or long, a needle is needed to heal the wound, mainly depending on the regeneration of the skin. All these methods, in daily life, inevitably present the risk of wound suppuration or further infection due to the environment of the body. Therefore, accelerating wound healing, epidermal growth, is an effective way to reduce further infection of the wound.

Therefore, the need for an effective way to reduce further infection of a wound is a problem that those skilled in the art are demanding to solve.

Disclosure of Invention

The invention provides a cell preparation for wound healing, which aims to solve the technical problems, accelerates wound healing and improves the wound repair rate through the synergistic effect generated by components in the cell preparation. The technical scheme adopted by the invention is as follows:

a cell preparation for wound healing comprises the following components in parts by weight: 10-50 parts of polyacrylamide, 2-25 parts of chitosan quaternary ammonium salt, 1-25 parts of quercetin and 1-20 parts of platelet-rich plasma. The cell preparation for wound healing is compounded by polyacrylamide, chitosan quaternary ammonium salt and the platelet-rich plasma of quercetin, so that the synergistic effect is generated between the quercetin and the platelet-rich plasma, the wound healing can be accelerated, and the wound repair rate is improved.

Preferably, the volume ratio of the quercetin to the platelet rich plasma of the cell preparation for wound healing is 1-9: 1-9. The inventor finds that the two have better wound repair effect within the ratio range through a large number of experiments.

Preferably, the cell preparation for wound healing has a volume ratio of quercetin to platelet rich plasma of 1: 1. The inventor finds that when the ratio of the wound surface and the wound surface is equal to the ratio, the wound can be completely healed within 12 days, the wound surface repair is accelerated, and the wound surface repair time is shortened.

Preferably, the cell preparation for wound healing comprises the following components in parts by weight: 20-40 parts of polyacrylamide, 10-20 parts of chitosan quaternary ammonium salt, 5-10 parts of quercetin and 10-15 parts of platelet-rich plasma.

Preferably, the cell preparation for wound healing comprises the following components in parts by weight: 30 parts of polyacrylamide, 15 parts of chitosan quaternary ammonium salt, 10 parts of quercetin and 10 parts of platelet-rich plasma.

The invention has the beneficial effects that: the cell preparation for wound healing provided by the invention contains platelet-rich plasma derived from umbilical cord blood, has abundant fibrin, and more effectively supports wound healing than adult peripheral blood. By the synergistic effect of the platelet-rich plasma and the quercetin, the wound healing is accelerated, the wound repair rate is improved, the wound repair time is shortened, the wound repair rate can reach more than 60% on the 8 th day after the cell preparation is smeared, and the wound can be completely healed in 12 days at the fastest speed.

Detailed Description

In order to show technical solutions, purposes and advantages of the present invention more concisely and clearly, the technical solutions of the present invention are described in detail below with reference to specific embodiments.

Example 1

The components of the composite cell preparation comprise the following components in parts by weight: 10 parts of polyacrylamide, 2 parts of chitosan iodide quaternary ammonium salt, 1 part of quercetin and 1 part of platelet-rich plasma.

Example 2

The components of the composite cell preparation comprise the following components in parts by weight: 20 parts of polyacrylamide, 10 parts of chitosan iodide quaternary ammonium salt, 15 parts of quercetin and 2 parts of platelet-rich plasma.

Example 3

The components of the composite cell preparation comprise the following components in parts by weight: 30 parts of polyacrylamide, 15 parts of chitosan iodide quaternary ammonium salt, 10 parts of quercetin and 10 parts of platelet-rich plasma.

Example 4

The components of the composite cell preparation comprise the following components in parts by weight: 40 parts of polyacrylamide, 20 parts of chitosan iodide quaternary ammonium salt, 5 parts of quercetin and 15 parts of platelet-rich plasma.

Example 5

The components of the composite cell preparation comprise the following components in parts by weight: 50 parts of polyacrylamide, 25 parts of chitosan iodide quaternary ammonium salt, 25 parts of quercetin and 20 parts of platelet-rich plasma.

Comparative example 1

The components of the composite cell preparation comprise the following components in parts by weight: 30 parts of polyacrylamide, 15 parts of chitosan iodide quaternary ammonium salt and 20 parts of platelet-rich plasma.

Comparative example 2

The components of the composite cell preparation comprise the following components in parts by weight: 30 parts of polyacrylamide, 15 parts of chitosan iodide quaternary ammonium salt and 20 parts of quercetin.

Test example 1

The effect of the compound cell preparation prepared in the above examples 1-5 and comparative examples 1 and 2 on wound healing can be tested by animal experiments. The animal experiment is as follows:

dissolving chitosan iodide quaternary ammonium salt in water to enable the final working concentration to be 1 mg/ml;

dissolving quercetin in ethanol solution to obtain final working concentration of 1 μmol/ml;

animal model experiment I:

grouping: 24C 57BL/6 male mice, 25 + -2 g weight, 23 + -1 deg.C laboratory temperature, 60 + -5% humidity, natural lighting, free feeding. 24 mice were divided into four groups, namely (I) a control group (TMCI aqueous solution), (II) a PRP group (comparative example 1), (III) a quercetin group (comparative example 2), and (III) a PRP-quercetin group (examples 1 to 5), each group being supplemented with TMCI at a concentration of 1 mg/ml.

Modeling: a local skin full-layer excision wound model is manufactured on the back of a mouse, a full-layer skin excision window is built in an operation area, the skin is deep under the skin, bleeding is naturally stopped, binding is not needed, and the wound is kept dry. The Control group was coated with TMCI aqueous solution, and the other groups were coated with the corresponding cell preparations, respectively. Wound surface area measurements were performed at 2 nd, 4 th, 6 th, and 8 th, respectively, and the wound surface repair rate was (original wound surface area-measured area)/original wound surface area × 100%. The results of the experiment are shown in table 1:

table 1: results of wound repair with cell preparations of examples 1 to 5 and comparative examples 1 and 2

Group of	2d(％)	4d(％)	6d(％)	8d(％)	10d(％)	12d(％)
							Control group	5.9	7.3	10.9	15.4	23.7	35.8
Comparative example 1	12.1	23.4	35.5	45.6	53.2	62.2
							Comparative example 2	13.8	21.1	32.2	41.1	60.5	68.8
Example 1	21.3	32.2	45.4	62.3	78.1	82.2
							Example 2	23.1	36.4	48.5	69.6	80.2	90.1
Example 3	22.3	59.2	68.4	85.3	92.5	100
							Example 4	20.8	38.5	56.8	62.8	78.8	96.2
Example 5	25.3	42.2	62.4	76.3	85.2	96.4

As can be seen from table 1, the wound repair rate of the cell preparations of examples 1 to 5 is significantly higher than that of comparative examples 1 and 2, because one of quercetin solution and platelet-rich plasma is absent in the comparative examples, it can be seen that in the composite cell preparation of the present invention, the synergistic effect is generated due to the combination of quercetin solution and platelet-rich plasma, so that the wound repair rate of the cell preparation of the present invention can be significantly improved. Therefore, the examples 1 to 5 show that the wound repair rate of the mouse wound reaches more than 60% from 8 days, while the comparative example is only 40%, so that the composite cell preparation can repair the wound in advance and accelerate the healing of the wound. Meanwhile, as can be seen from examples 1 to 5, the repair rate of example 3 on day 10 is higher than that of other examples, which indicates that example 3 may be the best scheme of the present invention.

Experimental example 2

In order to determine the optimal ratio of quercetin to platelet rich plasma in the cell preparation of the present invention, the inventors designed the following animal experiments:

animal model experiment II:

modeling: a local skin full-layer excision wound model is manufactured on the back of a mouse, a full-layer skin excision window is built in an operation area, the skin is deep under the skin, bleeding is naturally stopped, binding is not needed, and the wound is kept dry. The Control group and other component groups are respectively coated with corresponding components. Wound area measurements were performed on days 2, 4, 6, 8, 10, and 12, and the wound repair rate was (original wound area-measured area)/original wound area × 100%.

Grouping: 36C 57BL/6 male mice, 25 + -2 g weight, 23 + -1 deg.C laboratory temperature, 60 + -5% humidity, natural lighting, free feeding. The mice were divided into 6 groups, each of which was as follows:

control group (TMCI aqueous solution); ② PRP-quercetin-a group (volume ratio 1:9, example 6); ③ PRP-quercetin-b group (volume ratio 3:7, example 7); PRP-Quercetin-c group (volume ratio 1:1, example 3); PRP-Quercetin-d group (volume ratio 7:3, example 8); sixthly, PRP-quercetin-e group (volume ratio 9:1, example 9). The results of the experiment are shown in table 2 below:

table 2: results of wound repair with the cell preparations of the above 6 groups

As can be seen from table 2, although the quercetin and the platelet-rich plasma can generate synergistic effect and improve the repair rate of the wound surface, the ratio of the two components will ultimately affect the repair effect of the cell preparation of the present invention, for example, when the volume ratio of PRP to quercetin in experiments a and b is 1:9 and 3:7, the repair rate after 12 days is 80%, and when the volume ratio of PRP to quercetin in experiments d and e is 7:3 and 1:9, the repair rate after 12 days is 90%, while the repair rate in c reaches 100%, and the wound surface is completely healed. Therefore, the ratio of the quercetin to the platelet-rich plasma influences the repairing effect of the cell preparation, and when the volume ratio of the quercetin to the platelet-rich plasma is 1:1, which is finally obtained through a large number of experiments by the inventor, the wound surface is completely repaired for only 12 days, so that the healing time of the wound is greatly shortened.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.